STOCK TITAN

Vanguard amendment shows 0 shares of 4D Molecular (NASDAQ: FDMT)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

4D Molecular Therapeutics Inc Schedule 13G/A amendment reports that The Vanguard Group holds 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that led certain Vanguard subsidiaries to report separately.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports no beneficial ownership after internal realignment.

The filing states Amount beneficially owned: 0 and Percent of class: 0%, indicating Vanguard does not claim beneficial ownership of 4D Molecular's common stock in this amendment. The disclosure cites SEC Release No. 34-39538 regarding disaggregation.

Cash-flow treatment and trading intentions are not stated; subsequent filings would show any holdings reaggregation or separate subsidiary reports.

Amendment documents compliance with SEC disaggregation guidance.

The text explains that Vanguard reorganized and that certain subsidiaries will report separately, consistent with SEC guidance. The filing includes the standard ownership table showing zeros for voting and dispositive powers.

This is an administrative/update filing; material impact depends on later separate reports by Vanguard entities.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does The Vanguard Group report for FDMT ownership?

The filing states Amount beneficially owned: 0 and Percent of class: 0%. It records zero voting and dispositive power over FDMT common stock in this amendment.

Why did Vanguard file this Schedule 13G/A for FDMT?

Vanguard explains an internal realignment on January 12, 2026 and cites SEC Release No. 34-39538, stating certain subsidiaries will report beneficial ownership separately from The Vanguard Group.

Does this filing show any shares controlled by Vanguard subsidiaries for FDMT?

No; the amendment lists all voting and dispositive power entries as 0. It notes subsidiaries will report separately, but this filing records no holdings by The Vanguard Group itself.

Who signed the FDMT Schedule 13G/A amendment for Vanguard?

The filing is signed by Ashley Grim, titled Head of Global Fund Administration, with signature date 03/26/2026.

Does the filing identify any party with more than 5% ownership of FDMT?

The amendment states that no one other person's interest in the securities reported is more than 5%, and classifies the position as ownership of 5 percent or less of a class.
4D Molecular Therapeutics Inc.

NASDAQ:FDMT

View FDMT Stock Overview

FDMT Rankings

FDMT Latest News

FDMT Latest SEC Filings

FDMT Stock Data

504.39M
49.15M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
EMERYVILLE